OncoCyte Corporation

OncoCyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. The company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. OncoCyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. For more information, visit www.oncocyte.com.